Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961971 | 0.92 | AVPR2 (0.37) | JAK2BRD4PARP1MAP3K7ABL1 | |
| SCHEMBL7967361 | 0.91 | BRD4 (0.36) | JAK2BRD4PARP1MAP3K7ABL1 | |
| SCHEMBL7969777 | 0.88 | JAK2 (0.39) | JAK2BRD4PARP1MAP3K7ABL1 | |
| SCHEMBL7954153 | 0.87 | MAP3K7 (0.37) | BRD4PARP1MAP3K7IRAK4 | |
| SCHEMBL7596836 | 0.87 | MAP3K7 (0.36) | BRD4PARP1MAP3K7IRAK4PTGES | |
| Hydrochloric Acid SCHEMBL7966670 | 0.87 | MAP3K7 (0.37) | BRD4PARP1MAP3K7IRAK4 | |
| SCHEMBL7964818 | 0.87 | PDE3B (0.35) | BRD4PARP1 | |
| Hydrochloric Acid SCHEMBL7975724 | 0.86 | PTGES (0.36) | MAP3K7PTGES | |
| SCHEMBL7966353 | 0.86 | TSHR (0.38) | BRD4PARP1IRAK4PTGESTSHR | |
| SCHEMBL7482373 | 0.86 | BRD4 (0.34) | BRD4PARP1IRAK4PTGESTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |